HK1154054A1 - Predictors of patient response to treatment with egf receptor inhibitors - Google Patents

Predictors of patient response to treatment with egf receptor inhibitors

Info

Publication number
HK1154054A1
HK1154054A1 HK11108366.6A HK11108366A HK1154054A1 HK 1154054 A1 HK1154054 A1 HK 1154054A1 HK 11108366 A HK11108366 A HK 11108366A HK 1154054 A1 HK1154054 A1 HK 1154054A1
Authority
HK
Hong Kong
Prior art keywords
predictors
treatment
egf receptor
receptor inhibitors
patient response
Prior art date
Application number
HK11108366.6A
Other languages
English (en)
Inventor
Joffre B Baker
Drew Watson
Tara Maddala
Steven Shak
David J Mauro
Shirin K Ford
Original Assignee
Genomic Health Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc, Bristol Myers Squibb Co filed Critical Genomic Health Inc
Publication of HK1154054A1 publication Critical patent/HK1154054A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11108366.6A 2008-05-14 2011-08-10 Predictors of patient response to treatment with egf receptor inhibitors HK1154054A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12781608P 2008-05-14 2008-05-14
PCT/US2009/043823 WO2009140409A1 (en) 2008-05-14 2009-05-13 Predictors of patient response to treatment with egf receptor inhibitors

Publications (1)

Publication Number Publication Date
HK1154054A1 true HK1154054A1 (en) 2012-04-20

Family

ID=41319044

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11108366.6A HK1154054A1 (en) 2008-05-14 2011-08-10 Predictors of patient response to treatment with egf receptor inhibitors

Country Status (9)

Country Link
US (2) US8273534B2 (xx)
EP (2) EP2615183B1 (xx)
AU (1) AU2009246398A1 (xx)
CA (1) CA2723984A1 (xx)
DK (1) DK2288727T3 (xx)
ES (1) ES2430590T3 (xx)
HK (1) HK1154054A1 (xx)
NZ (3) NZ610482A (xx)
WO (1) WO2009140409A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
WO2010127322A1 (en) * 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
KR20120047912A (ko) * 2009-06-19 2012-05-14 메르크 파텐트 게엠베하 암 요법에서 항ｅｇｆｒ 항체의 효능을 결정하기 위한 바이오마커 및 방법
EP3257950B1 (en) * 2010-09-28 2020-04-08 Agendia N.V. Methods and means for typing a sample comprising cancer cells based on oncogenic signal transduction pathways
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP2718485A4 (en) * 2011-06-07 2015-05-06 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
WO2013052480A1 (en) * 2011-10-03 2013-04-11 The Board Of Regents Of The University Of Texas System Marker-based prognostic risk score in colon cancer
AU2013208757A1 (en) * 2012-01-09 2014-07-24 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
CN105407913A (zh) * 2012-07-31 2016-03-16 中美冠科生物技术（太仓）有限公司 用于鉴定可用抗egfr药物治疗的食管癌患者的生物标志物
WO2014028222A1 (en) * 2012-07-31 2014-02-20 Crown Bioscience, Inc. Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
WO2014071226A1 (en) * 2012-11-02 2014-05-08 The Regents Of The University Of California Methods and systems for determining a likelihood of adverse prostate cancer pathology
GB201223025D0 (en) * 2012-12-20 2013-02-06 Medizinische Universitaet Graz Prediction of the treatment response to an anti-EGFR molecule in colorectal cancer patients
SG11201607448PA (en) * 2014-03-11 2016-10-28 Queensland Inst Med Res Determining cancer agressiveness, prognosis and responsiveness to treatment
US20160024585A1 (en) * 2014-05-02 2016-01-28 Duke University Methods of predicting responsiveness of a cancer to an agent and methods of determining a prognosis for a cancer patient
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
FR3037403A1 (fr) * 2015-06-12 2016-12-16 Centre Leon Berard Procede de prediction de la sensibilite d'une tumeur gastro-intestinale a un traitement inhibiteur
CN106148533B (zh) * 2016-07-28 2019-06-11 北京泱深生物信息技术有限公司 用于食管鳞癌诊治的标志物
WO2018078143A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
WO2020080871A2 (ko) * 2018-10-18 2020-04-23 (주)신테카바이오 암 약물 반응성 판단을 위한 바이오 마커 조성물, 바이오 마커 조성물을 이용한 암 약물 반응성 판단 방법 및 암 약물 반응성 판단을 위한 바이오 마커 조성물 검출용 진단칩

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
EP1813684A3 (en) 1994-02-14 2009-11-18 Smithkline Beecham Corporation Differently expressed genes in healthy and diseased subjects
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
DE69613367T2 (de) 1995-04-27 2002-04-18 Astrazeneca Ab, Soedertaelje Chinazolin derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
ES2174250T5 (es) 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
ES2486265T3 (es) * 2002-03-13 2014-08-18 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados
CA2478640A1 (en) * 2002-03-13 2003-09-18 F. Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CA2516553C (en) 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
EP2226396A1 (en) 2003-05-30 2010-09-08 Genomic Health, Inc. Gene expression markers for response to EGFR inhibitor drugs
CN101193905B (zh) 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 用于检测抗药egfr突变体的方法和组合物
US20070009267A1 (en) * 2005-06-22 2007-01-11 Crews Darren S Driving a laser using an electrical link driver
DK1913157T4 (en) 2005-06-28 2017-01-23 Genentech Inc EGFR and KRAS mutations for predicting patient response to EGFR inhibitor therapy.
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
EP1917528B1 (en) * 2005-08-24 2011-08-17 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
NZ593228A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (inhba) for colorectal cancer prognosis
EP2140020A2 (en) 2007-03-15 2010-01-06 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2010127322A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy

Also Published As

Publication number Publication date
NZ589143A (en) 2012-02-24
WO2009140409A1 (en) 2009-11-19
EP2288727A4 (en) 2011-09-14
US20090298701A1 (en) 2009-12-03
EP2288727A1 (en) 2011-03-02
EP2615183B1 (en) 2014-10-08
EP2615183A1 (en) 2013-07-17
EP2288727B1 (en) 2013-07-10
AU2009246398A1 (en) 2009-11-19
CA2723984A1 (en) 2009-11-19
DK2288727T3 (da) 2013-10-21
NZ597292A (en) 2013-06-28
ES2430590T3 (es) 2013-11-21
US20120270228A1 (en) 2012-10-25
US8273534B2 (en) 2012-09-25
NZ610482A (en) 2014-08-29

Similar Documents

Publication Publication Date Title
HK1154054A1 (en) Predictors of patient response to treatment with egf receptor inhibitors
IL259475A (en) Combined therapy for the treatment of diabetes
HK1173654A1 (zh) 治療化合物及相關的使用方法
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
GB0908316D0 (en) Thermal treatment of biomass
ZA201006648B (en) Methods of treatment
HK1169804A1 (zh) 治療疼痛的方法
GB0915515D0 (en) Treatment of vasculoproliferative conditions
IL206491A0 (en) Treatment of produce
GB0902040D0 (en) Composition for treatment of skin
IL215245A0 (en) Use of nkp46 for preventing diabetes
HK1160925A1 (zh) 組織蛋白酶 的用途
HK1156250A1 (en) Unit dosage of apadenoson
ZA201101204B (en) Novel use application of sugar chain-recognizing receptor
GB0802903D0 (en) Treatment of diabetes
HU0800656D0 (en) Effective use of tea-composition
IL214075A0 (en) Use of pc for treatment follow up
GB0809936D0 (en) Therapeutic use of zolpidem
GB0819854D0 (en) Therapeutic use of zolpidem
GB0922058D0 (en) Treatment of bipolar disorder
GB0802904D0 (en) Treatment of metabolic syndrome